GILD Gilead Sciences Inc.

Gilead Sciences Announces Fourth Quarter 2016 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.47 per share of common stock for the fourth quarter of 2016. The dividend is payable on December 29, 2016, to stockholders of record at the close of business on December 15, 2016. Future dividends will be subject to Board approval.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

EN
01/11/2016

Underlying

GILDGilead Sciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gilead Sciences Inc.

GILD Gilead Sciences...

Gilead Sciences, Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GILD GILEAD SCIENCES INC.
12/12/25 December 12, 2025 1 EN
Free Trial
GILD Gilead Sciences...

Gilead Sciences Inc: 3 directors

Three Directors at Gilead Sciences Inc sold/sold after exercising options 20,611 shares at between 125.080USD and 127.105USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...

GILD GILEAD SCIENCES INC.
12/02/25 December 2, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.41
INCY INCYTE CORP
TECH Bio-Techne Corp... ... (+26)

Vermilion Compass: Weekly Equity Strategy

Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...

INCY INCYTE CORP
TECH BIO-TECHNE CORPORATION
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
GILD GILEAD SCIENCES INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
ENS ENERSYS
BIIB BIOGEN INC.
BGNE BEIGENE LTD. SPONSORED ADR
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALNY ALNYLAM PHARMACEUTICALS INC
IONS IONIS PHARMACEUTICALS INC.
UTHR UNITED THERAPEUTICS CORPORATION
MDGL MADRIGAL PHARMACEUTICALS
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
QS QUANTUMSCAPE
ENVX ENOVIX CORP
FLNC FLUENCE ENERGY INC
SLDP SOLID POWER INC
MVST MICROVAST HLDGS INC
AMPX AMPRIUS TECHNOLOGIES INC
SES SES AI CORPORATION
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
TE ALUSSA ENERGY ACQUISITION CORP
10/08/25 October 8, 2025 1 EN
GILD Gilead Sciences...

Moody's Ratings affirms Gilead's A3 rating; revises outlook to positiv...

Moody's Ratings (Moody's) affirmed the ratings of Gilead Sciences, Inc. ("Gilead") including the A3 senior unsecured ratings and (P)A3 senior unsecured shelf rating. At the same time, we revised the outlook to positive from stable. The positive outlook reflects positive momentum in Gilead's pipeli...

GILD GILEAD SCIENCES INC.
09/18/25 September 18, 2025 1 EN
GILD GILEAD SCIENCES INC.
12/18/24 December 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch